South Dakota Senate Bill 75, a biosimilar substitution bill, is expected to be signed by South Dakota’s Governor, Dennis Daugaard-R.
In the United States, 9 biosimilars have currently earned FDA approval, with 3 available on the market today. Despite slower biosimilar uptake than originally projected, many states have been introducing legislation for the marketing and potential substitution of biosimilars in preparation for their increased availability and eventual interchangeable status. To date, 37 states and Puerto Rico have passed legislation on biologics and biosimilar substitution, according to the National Conference of State Legislature, with South Dakota becoming the most recent state to have its legislature pass a biologics and biosimilar substitution bill.
South Dakota Senate Bill 75, which is expected to be signed by South Dakota’s Governor, Dennis Daugaard-R, allows pharmacists to substitute an interchangable biosimilar for its reference without the intervention of the prescribing healthcare provider, unless the reference is specifically called for by the prescriber.
However, if a substitution is made, the pharmacist is required to notify the patient when the drug is dispensed (and inform the patient of their right to refuse the biosimilar), and must also notify the prescriber within 5 business days. In addition, the bill requires records of a biologic substitution to be kept either electronically or in hard copy, and provides guidelines for how to label such products (ie, using the product's proper name or brand name).
Senate Bill 75, as well as many other state bills follow the principles endorsed by Biotechnology Innovation Organization (BIO), a biotech industry trade group, which hold that substitution should occur only when the product has the FDA’s interchangeable designation, that prescribers should be able to prevent substitution, that physicians and patients should be notified if substitution occurs, and that good records of substitution must be maintained.
Senate Bill 75 was delivered to Governor Daugaard for signing on February 6.
BIO voiced its support for passage of the bill, saying in a statement that, while almost 90% of the US population is now covered by state laws addressing biosimilar substitution, it “…will keep up the pressure until all 50 states enact this important public policy.”
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.